心血管病防治知识（下半月）
心血管病防治知識（下半月）
심혈관병방치지식（하반월）
XINXUEGUANBING FANGZHI ZHISHI
2013年
10期
22-23
,共2页
先天性心脏病%介入治疗%临床疗效分析
先天性心髒病%介入治療%臨床療效分析
선천성심장병%개입치료%림상료효분석
Levamlodipine besylate%Sustained-release tablets of nifedipine%Primary hypertension%Clinical efficacy
目的：探讨介入治疗应用与先天性心脏病（CHD）的临床疗效，并对结果进行分析。方法选取108例CHD患者，均采用介入治疗方法，其中45例患者应用房间隔缺损（ASD）封堵术，39例患者应用室间隔缺损（VSD）封堵术，24例例患者应用动脉导管未闭（PDA）封堵术。结果105例患者被治愈，治疗成功率为97.22%，3例患者发生了各种并发症，并发症发生率为2.78%。结论介入治疗应用于CHD具有创伤面积较小、成功率较高、并发症及死亡率较低等特点，临床疗效显著，对于大多数CHD患者来说可替代外科手术，值得临床应用及推广。
目的：探討介入治療應用與先天性心髒病（CHD）的臨床療效，併對結果進行分析。方法選取108例CHD患者，均採用介入治療方法，其中45例患者應用房間隔缺損（ASD）封堵術，39例患者應用室間隔缺損（VSD）封堵術，24例例患者應用動脈導管未閉（PDA）封堵術。結果105例患者被治愈，治療成功率為97.22%，3例患者髮生瞭各種併髮癥，併髮癥髮生率為2.78%。結論介入治療應用于CHD具有創傷麵積較小、成功率較高、併髮癥及死亡率較低等特點，臨床療效顯著，對于大多數CHD患者來說可替代外科手術，值得臨床應用及推廣。
목적：탐토개입치료응용여선천성심장병（CHD）적림상료효，병대결과진행분석。방법선취108례CHD환자，균채용개입치료방법，기중45례환자응용방간격결손（ASD）봉도술，39례환자응용실간격결손（VSD）봉도술，24례례환자응용동맥도관미폐（PDA）봉도술。결과105례환자피치유，치료성공솔위97.22%，3례환자발생료각충병발증，병발증발생솔위2.78%。결론개입치료응용우CHD구유창상면적교소、성공솔교고、병발증급사망솔교저등특점，림상료효현저，대우대다수CHD환자래설가체대외과수술，치득림상응용급추엄。
Objective To investigate the clinical efficacy of levamlodipine besylate in the treatment of primary hypertension. Methods A total of 122 patients with primary hypertension who visited our hospital from February 2011 to February 2013 were randomly divided into study group and control group. The control group received sustained-release tablets of nifedipine, while the study group received levamlodipine besylate. The treatment outcomes of the two groups (changes in blood pressure, overall response rate, and adverse reactions) were observed, analyzed, and compared.Results Both groups showed significant decreases in blood pressure after treatment (P<0.05). The study group had a significantly higher overall response rate than the control group [91.80% (56/61) vs 80.33% (49/61), P<0.05]. The study group had a significantly lower incidence of adverse events than the control group [6.56% (4/61) vs 18.03% (11/61), P<0.05].ConclusionThe patients with primary hypertension have good treatment compliance and hypertension outcome and low incidence of adverse events when treated with levamlodipine besylate. Levamlodipine besylate holds promise for clinical application.
